PRESTO-F: PREhospital Routage of Acute STroke Patients With Suspected Large Vessel Occlusion: Mothership Versus Drip and Ship

Sponsor
University Hospital, Caen (Other)
Overall Status
Recruiting
CT.gov ID
NCT04121013
Collaborator
(none)
800
1
2
11
72.5

Study Details

Study Description

Brief Summary

Background: The outcome of ischemic stroke is related to the brain lesion volume and this volume of infarction is directly related to the time to reperfusion, which therefore depends on the time to initiation of therapy. Acute ischemic stroke is treated medically with the administration of intravenous rtPA, but recent randomized controlled trials have shown the efficacy of mechanical thrombectomy and is now the new gold standard in ischemic stroke. This new therapeutic strategy has created two possibilities for pre-hospital decision-making: i/ transport the patient directly to the nearest stroke unit to receive alteplase and then if indicated perform a thrombectomy (drip and ship) or ii/ bypassing thrombolysis centres in favour of endovascular thrombectomy (mothership).

Objective: To compare cost/effectiveness of transfer to the closest local stroke centre or telemedicine hub to direct transfer to the comprehensive stroke cent(CSC) in patients acute stroke with suspected large vessel occlusion.

Medical and economic expected impact: We hypothesize that direct transportation to CSC is associated with better clinical outcome in case of acute ischaemic stroke due to intracranial large vessel occlusion. However, we have to demonstrate that this approach is not associated with time from onset harm in patients not eligible to mechanical thrombectomy.

Condition or Disease Intervention/Treatment Phase
  • Other: mothership
N/A

Detailed Description

Design: Multicenter, two-arm, prospective, open, blinded end-point (PROBE), randomized, clinical trial

Primary endpoint: Incremental cost-utility ratio at 12 months. Secondary endpoints: modified Rankin scale and EuroQoL5D scale at 3 months.

Eligibility criteria: A call to the emergency medical assistance service, 18 years and older, severe acute stroke symptoms, transportation time from scene to the CSC longer than time to go to the nearest stroke unit or telemedicine hub, transportation time from scene to the CSC compatible with IV thrombolysis, known time from onset, RACE score (assessed by medical emergency technicians) ≥5.

Experimental arm: direct transportation to the CSC. Control arm: transfer to the closest local stroke centre or telemedicine hub.

Sample size: 800 patients, 400 for each arm.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
800 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Health Services Research
Official Title:
PREhospital Routage of Acute STroke Patients With Suspected Large Vessel Occlusion: Mothership Versus Drip and Ship, a Randomized Control Study in France (PRESTO-F)
Actual Study Start Date :
Jan 30, 2021
Anticipated Primary Completion Date :
Jan 1, 2022
Anticipated Study Completion Date :
Jan 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Mothership

Acute stroke patients with suspected large vessel occlusion will be directly transferred to the nearest transportation to the endovascular center

Other: mothership
Randomized controlled study: allocation to active or no intervention arm will be done accordingly to the design temporal sequence

No Intervention: drip'n'ship

Acute stroke patients with suspected large vessel occlusion will be transferred to the closest local stroke centre or telemedicine hub as done with the current stroke protocol

Outcome Measures

Primary Outcome Measures

  1. Incremental cost-utility ratio [12 months]

    Incremental cost-utility ratio (ICUR) at 12 months, defined as the ratio of the incremental cost of management by transfer to a CSC with MT (compared to the control arm "local PSC") to the gain in healthy survival (quality adjusted life years, QALYs).

Secondary Outcome Measures

  1. modified Rankin scale score [90 days]

    is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death. Modified Rankin Scale score will be evaluated through a structured telephone-based interview performed by a central assessor who is blinded to group assignment

Other Outcome Measures

  1. EuroQoL5D scale [90 days]

    EQ-5D is a standardized instrument for measuring generic health status. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. EuroQol5D scale will be evaluated through a structured telephone-based interview performed by a central assessor who is blinded to group assignment

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • A call to the emergency medical assistance service;

  • age> 18y,

  • known time of stroke onset;

  • transportation time from scene to the CSC longer than time to go to the nearest stroke unit or telemedicine hub;

  • transportation time from scene to the CSC compatible with IV thrombolysis;

  • known time from onset, RACE score ≥5.

Exclusion Criteria:
  • transportation time from scene to the CSC longer than time to go to the nearest stroke unit or telemedicine hub.

  • no ambulance available

  • bedridden patient

Contacts and Locations

Locations

Site City State Country Postal Code
1 University hospital of Caen Caen Normanide France 14000

Sponsors and Collaborators

  • University Hospital, Caen

Investigators

  • Principal Investigator: Emmanuel Touze, Pr, University hospital of Caen

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Caen
ClinicalTrials.gov Identifier:
NCT04121013
Other Study ID Numbers:
  • 2018-A02873-52
First Posted:
Oct 9, 2019
Last Update Posted:
Apr 14, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Caen
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 14, 2021